对伊朗非膜性心房的抗凝选择的成本效益分析
Satar Rezaei1, Maryam Bavandpour2, Mohammadreza Mobinizadeh3
1Research Center for Environmental Determinants of Health, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
BMC research notes
|November 27, 2024
概括
阿皮克萨班是伊朗非膜动 (NVAF) 的最具成本效益的抗凝药,提供优质调整寿命年 (QALYs) 和达到支付意愿门的高概率. 这一发现支持优化医疗保健支出和改善患者治疗结果.
科学领域:
- 药物经济学 药物经济学
- 卫生经济学 卫生经济学
- 临床决策 临床决策
背景情况:
- 心房动 (AF) 是一个重大的经济和临床挑战,特别是在像伊朗这样的发展中国家.
- 非膜性心房动 (NVAF) 的管理需要仔细考虑治疗成本和患者的治疗结果.
研究的目的:
- 评估伊朗NVAF患者各种抗凝固疗法的成本效益.
- 从医疗保健支付人的角度来看,比较华法林,阿皮克萨班,达比加特兰和里瓦罗克萨班.
主要方法:
- 使用终身地平线马尔科夫模型进行成本效益分析.
- 纳入临床事件率,病例死亡率和实用值.
- 敏感性分析 (确定性和概率) 来评估不确定性.
主要成果:
- 阿皮克萨班产生的最高质量调整寿命年 (QALYs) 为7.33.
- 阿皮克萨班表现出最有利的成本效益,每QALY获得的ICER为2,026美元,与华法林相比.
- 阿皮克萨班在其他策略中占主导地位,提供更低的成本和更高的QALY,在伊朗的门上,成本效益的概率为88.2%.
结论:
- 阿皮克萨班是一种非常具有成本效益的治疗选择,用于伊朗的NVAF.
- 这些发现支持医疗保健决策者优化NVAF的治疗策略.
- 采用阿皮克萨班可能会改善患者的治疗结果和更有效地分配医疗保健资源.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
623
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
623
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
910
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
910
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K


